Averbuch M, Katzper M
Division of Analgesic, Anti-inflammatory and Ophthalmic Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA.
Clin Pharmacol Ther. 2001 Sep;70(3):287-91. doi: 10.1067/mcp.2001.118366.
Our objective was to examine the placebo arms from a series of clinical trials in which the post-third molar extraction dental pain model was used to elucidate the time course of the placebo effect and the proportion of the population that are responders, as well as to evaluate whether the placebo analgesic response of female subjects may differ from that of male subjects.
We performed a meta-analysis of 596 subjects included in the placebo treatment arm of 16 double-blind, post-third molar extraction dental pain (moderate to severe) studies submitted to the Food and Drug Administration electronically. The inclusion and exclusion criteria were practically identical in all studies. Pain relief and pain intensity measurements used the same metrics in all studies. The measurements were recorded just before drug administration and at least at postdose hours 0.5, 1, 1.5, 2, 3, 4, 5, and 6.
There were 325 female subjects and 271 male subjects. They were all otherwise healthy, with a mean age of 21.6 years for female subjects and 22.3 years for male subjects. The postoperative baseline pain was greater in female subjects than in male subjects, and this difference was statistically significant. Both pain intensity and pain relief scores demonstrate the well-established placebo effect in 10% of the pooled subjects, as well as in all the individual studies. Over time, however, the mean pain intensity and pain relief scores for the female and male treatment groups were not noticeably different at any time point after medication. Further analysis of the data showed no gender difference in duration of action of the placebo.
The results demonstrated no gender difference in response to placebo. These results were obtained from the post-third molar extraction situation, in which the least possible confounding factors were present. To fully establish the generality of this phenomenon, studies should be carried out in other pain models.
我们的目的是研究一系列临床试验中的安慰剂组,这些试验采用第三磨牙拔除术后牙痛模型来阐明安慰剂效应的时间进程以及有反应者在人群中的比例,同时评估女性受试者的安慰剂镇痛反应是否可能与男性受试者不同。
我们对电子提交给美国食品药品监督管理局的16项双盲、第三磨牙拔除术后牙痛(中度至重度)研究的安慰剂治疗组中的596名受试者进行了荟萃分析。所有研究的纳入和排除标准基本相同。所有研究中疼痛缓解和疼痛强度测量均使用相同的指标。在给药前以及给药后至少0.5、1、1.5、2、3、4、5和6小时记录测量值。
有325名女性受试者和271名男性受试者。他们在其他方面均健康,女性受试者的平均年龄为21.6岁,男性受试者为22.3岁。女性受试者术后基线疼痛比男性受试者更严重,且这种差异具有统计学意义。疼痛强度和疼痛缓解评分在10%的汇总受试者以及所有个体研究中均显示出已确立的安慰剂效应。然而,随着时间的推移,女性和男性治疗组的平均疼痛强度和疼痛缓解评分在用药后的任何时间点均无明显差异。对数据的进一步分析表明安慰剂作用持续时间无性别差异。
结果表明对安慰剂的反应不存在性别差异。这些结果来自第三磨牙拔除术后的情况,其中存在的混杂因素最少。为了全面确定这一现象的普遍性,应在其他疼痛模型中进行研究。